ArticleNPJ precision oncology2025
Higher local recurrence as the distinct failure pattern in early-onset rectal cancer: a tailored MRI score to guide therapy.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The unique biology of early-onset locally advanced rectal cancer (EOLARC) may drive distinct failure patterns, challenging current age-agnostic management. This multicenter retrospective study aimed to define these patterns compared to late-onset disease (LOLARC) and develop a tailored magnetic resonance imaging (MRI)-based risk score. We analyzed 1289 patients undergoing neoadjuvant chemoradiotherapy and surgery. After propensity score matching, EOLARC patients exhibited higher local recurrence rates (4.9% vs. 1.7%; P = 0.03) despite similar pathological complete response (pCR) rates (25.5% vs. 21.2%; P = 0.22). The novel mrTML score (incorporating tumor deposits, mesorectal fascia, and lateral lymph nodes) effectively predicted local recurrence (adjusted hazard ratio for score 3 vs. 0, 33.99). Notably, high pre-treatment risk persisted even among patients achieving pCR (HR 12.02; P = 0.003), highlighting failure patterns uncaptured by pathological response. The mrTML score is a robust tool to identify patients at high risk for local recurrence, providing an evidence-based framework for risk-adapted therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.